President Trump's October 2025 directive to resume U.S. nuclear explosive testing on an "equal basis" with rivals sparked initial market attention, yet no such detonation has occurred amid a voluntary moratorium in place since 1992. Recent developments center on non-nuclear chemical high-explosive experiments conducted by the National Nuclear Security Administration at the Nevada National Security Site in September 2026, aimed at refining detection algorithms for low-yield or decoupled foreign tests rather than advancing U.S. explosive capabilities. Congressional opposition, including from key senators, and statements from NNSA and military leaders affirming the sufficiency of stockpile stewardship programs have reinforced trader views of low near-term probability. Diplomatic talks with China over alleged past tests and internal planning timelines of six to 36 months for any potential resumption further shape the cautious consensus reflected in current pricing.